002864 盘龙药业
交易中 09-16 10:33:39
资讯
新帖
简况
盘龙药业(002864)披露完成工商变更登记并换发营业执照公告,9月11日股价下跌2.61%
证券之星 · 09-11
盘龙药业(002864)披露完成工商变更登记并换发营业执照公告,9月11日股价下跌2.61%
股市必读:盘龙药业新发布《关于回购股份事项前十大股东及前十大无限售条件股东持股情况的公告》
证券之星 · 09-03
股市必读:盘龙药业新发布《关于回购股份事项前十大股东及前十大无限售条件股东持股情况的公告》
股市必读:盘龙药业新发布《关于回购股份事项前十大股东及前十大无限售条件股东持股情况的公告》
证券之星 · 09-02
股市必读:盘龙药业新发布《关于回购股份事项前十大股东及前十大无限售条件股东持股情况的公告》
盘龙药业(002864)披露回购公司股份进展情况公告,9月1日股价上涨2.84%
证券之星 · 09-01
盘龙药业(002864)披露回购公司股份进展情况公告,9月1日股价上涨2.84%
盘龙药业(002864)2026年中报简析:净利润同比下降29.53%
证券之星 · 08-29
盘龙药业(002864)2026年中报简析:净利润同比下降29.53%
盘龙药业中报:现金流激增夯实经营底盘,核心单品市场份额提升,中期分红叠加回购彰显发展信心
证券之星 · 08-28
盘龙药业中报:现金流激增夯实经营底盘,核心单品市场份额提升,中期分红叠加回购彰显发展信心
盘龙药业:业务结构升级落地显效,双资质加持打开新增长空间
中金财经 · 08-28
盘龙药业:业务结构升级落地显效,双资质加持打开新增长空间
股市必读:盘龙药业新发布《关于2026年半年度利润分配方案的公告》
证券之星 · 08-28
股市必读:盘龙药业新发布《关于2026年半年度利润分配方案的公告》
图解盘龙药业中报:第二季度单季净利润同比下降28.63%
证券之星 · 08-28
图解盘龙药业中报:第二季度单季净利润同比下降28.63%
股市必读:盘龙药业(002864)8月4日董秘有最新回复
证券之星 · 08-05
股市必读:盘龙药业(002864)8月4日董秘有最新回复
数十家机构扎堆调研!盘龙药业基药红利释放打开成长空间
中金财经 · 07-16
数十家机构扎堆调研!盘龙药业基药红利释放打开成长空间
盘龙药业(002864)披露2025年年度权益分派实施公告,7月15日股价上涨2.58%
证券之星 · 07-15
盘龙药业(002864)披露2025年年度权益分派实施公告,7月15日股价上涨2.58%
盘龙药业(002864)披露控股股东持股比例因回购注销被动增加触及1%及5%整数倍公告,7月14日股价上涨2.57%
证券之星 · 07-14
盘龙药业(002864)披露控股股东持股比例因回购注销被动增加触及1%及5%整数倍公告,7月14日股价上涨2.57%
盘龙药业:盘龙七片入选2026国家基药目录,凭硬核资质打开业绩增量空间
中金财经 · 07-10
盘龙药业:盘龙七片入选2026国家基药目录,凭硬核资质打开业绩增量空间
创新药概念震荡拉升,盘龙药业一度涨超9%
证券之星 · 06-23
创新药概念震荡拉升,盘龙药业一度涨超9%
盘龙药业:截至2026年一季度公司已完成509个中药配方颗粒品种备案
证券之星 · 06-04
盘龙药业:截至2026年一季度公司已完成509个中药配方颗粒品种备案
盘龙药业(002864)披露向2026年股票期权激励计划激励对象授予股票期权的公告,6月1日股价上涨1.91%
证券之星 · 06-01
盘龙药业(002864)披露向2026年股票期权激励计划激励对象授予股票期权的公告,6月1日股价上涨1.91%
盘龙药业(002864)披露2026年股票期权激励计划内幕信息知情人及激励对象买卖公司股票情况自查报告,5月27日股价下跌0.39%
证券之星 · 05-27
盘龙药业(002864)披露2026年股票期权激励计划内幕信息知情人及激励对象买卖公司股票情况自查报告,5月27日股价下跌0.39%
盘龙药业(002864)披露2026年股票期权激励计划(草案),5月13日股价上涨2.96%
证券之星 · 05-13
盘龙药业(002864)披露2026年股票期权激励计划(草案),5月13日股价上涨2.96%
盘龙药业(002864)披露召开2025年年度股东会的通知,5月6日股价上涨0.2%
证券之星 · 05-06
盘龙药业(002864)披露召开2025年年度股东会的通知,5月6日股价上涨0.2%
加载更多
公司概况
公司名称:
陕西盘龙药业集团股份有限公司
所属行业:
医药制造业
上市日期:
2017-11-16
主营业务:
陕西盘龙药业集团股份有限公司的主营业务是药材规范化种植、药品生产、研发、销售。公司的主要产品是盘龙七片、盘龙七药酒、金茵利胆胶囊、克比热提片、复方醋酸棉酚片、醋酸棉酚原料药、骨胶归珍片、盘龙七贴。截至本报告期末,公司荣获“国家级绿色工厂”及第七届“全国文明单位”,成功取得中国合格评定国家认可委员会(CNAS)实验室认可证书;2026年上半年新增获评“国家知识产权强国建设示范创建对象”“省级高技能人才培训基地”,入选“全国‘双化协同’典型案例”等多项荣誉资质。
发行价格:
10.03
{"stockData":{"symbol":"002864","market":"SZ","secType":"STK","nameCN":"盘龙药业","latestPrice":20.08,"timestamp":1789526019000,"preClose":20.26,"halted":0,"volume":839870,"delay":0,"changeRate":-0.0089,"floatShares":98596700,"shares":137000000,"eps":0.5744,"marketStatus":"交易中","change":-0.18,"latestTime":"09-16 10:33:39","open":20.32,"high":20.4,"low":20,"amount":16959300,"amplitude":0.0197,"askPrice":20.11,"askSize":2,"bidPrice":20.08,"bidSize":11,"shortable":0,"etf":0,"ttmEps":0.5744,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1789529400000},"marketStatusCode":2,"adr":0,"adjPreClose":20.26,"symbolType":"stock","openAndCloseTimeList":[[1789522200000,1789529400000],[1789534800000,1789542000000]],"highLimit":22.29,"lowLimit":18.23,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":136700928,"isCdr":false,"pbRate":1.6,"roa":"--","peRate":34.958217,"roe":"2.48%","epsLYR":0.92,"committee":0.648,"marketValue":2745000000,"turnoverRate":0.0085,"status":1,"floatMarketCap":1980000000},"requestUrl":"/m/hq/s/002864","defaultTab":"news","newsList":[{"id":"2666578977","title":"盘龙药业(002864)披露完成工商变更登记并换发营业执照公告,9月11日股价下跌2.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2666578977","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666578977?lang=zh_cn&edition=full","pubTime":"2026-09-11 22:35","pubTimestamp":1789137317,"startTime":"0","endTime":"0","summary":"近日,陕西盘龙药业集团股份有限公司披露《关于公司完成工商变更登记并换发营业执照的公告》。公告显示,公司因实施2025年度利润分配及资本公积金转增股本,以及回购注销2022年限制性股票,导致总股本和注册资本发生变化。变更后公司注册资本由10,628.096万元增至13,670.0928万元,总股本为136,700,928股。相关工商变更手续已办理完毕,并取得陕西省市场监督管理局颁发的新营业执照。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091100050651.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002864"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664846310","title":"股市必读:盘龙药业新发布《关于回购股份事项前十大股东及前十大无限售条件股东持股情况的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2664846310","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664846310?lang=zh_cn&edition=full","pubTime":"2026-09-03 02:50","pubTimestamp":1788375023,"startTime":"0","endTime":"0","summary":"公司公告汇总:披露回购决议前一交易日前十大股东及前十大无限售条件股东持股情况,谢晓林合计持股48,346,912股,其中无限售条件股份12,086,728股。公司公告汇总关于回购股份事项前十大股东及前十大无限售条件股东持股情况的公告陕西盘龙药业集团股份有限公司于2026年8月26日召开第五届董事会第九次会议,审议通过《关于以集中竞价交易方式回购公司股份方案的议案》。截至2026年8月31日,公司尚未实施回购,累计回购股份数量为0股,支付金额为0元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090300002340.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002864"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664865451","title":"股市必读:盘龙药业新发布《关于回购股份事项前十大股东及前十大无限售条件股东持股情况的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2664865451","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664865451?lang=zh_cn&edition=full","pubTime":"2026-09-02 02:44","pubTimestamp":1788288253,"startTime":"0","endTime":"0","summary":"公司公告汇总关于回购股份事项前十大股东及前十大无限售条件股东持股情况的公告陕西盘龙药业集团股份有限公司于2026年8月26日召开第五届董事会第九次会议,审议通过《关于以集中竞价交易方式回购公司股份方案的议案》。截至2026年8月27日,前十大股东中谢晓林持股48,346,912股,占总股本35.37%;前十大无限售条件股东中谢晓林持股12,086,728股,占无限售条件股份总数12.26%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090200002538.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002864","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664485703","title":"盘龙药业(002864)披露回购公司股份进展情况公告,9月1日股价上涨2.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664485703","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664485703?lang=zh_cn&edition=full","pubTime":"2026-09-01 22:58","pubTimestamp":1788274690,"startTime":"0","endTime":"0","summary":"截至2026年9月1日收盘,盘龙药业报收于22.45元,较前一交易日上涨2.84%,最新总市值为30.69亿元。近日,盘龙药业发布《关于回购公司股份进展情况的公告》。公告显示,公司于2026年8月26日召开第五届董事会第九次会议,审议通过以集中竞价交易方式回购公司股份的方案,拟用于员工持股计划或股权激励。回购期限为董事会审议通过之日起12个月内。截至2026年8月31日,公司尚未实施回购,累计回购股份数量为0股,支付金额为0元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090100043447.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002864"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663161150","title":"盘龙药业(002864)2026年中报简析:净利润同比下降29.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663161150","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663161150?lang=zh_cn&edition=full","pubTime":"2026-08-29 06:29","pubTimestamp":1787956185,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期盘龙药业发布2026年中报。根据财报显示,盘龙药业净利润同比下降29.53%。截至本报告期末,公司营业总收入4.23亿元,同比下降26.38%,归母净利润4237.61万元,同比下降29.53%。按单季度数据看,第二季度营业总收入2.0亿元,同比下降38.22%,第二季度归母净利润2061.52万元,同比下降28.63%。去年的净利率为8.42%,算上全部成本后,公司产品或服务的附加值一般。本文数据来源于盘龙药业2026年中报,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082900011442.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002864"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662054556","title":"盘龙药业中报:现金流激增夯实经营底盘,核心单品市场份额提升,中期分红叠加回购彰显发展信心","url":"https://stock-news.laohu8.com/highlight/detail?id=2662054556","media":"证券之星","labels":["dataReport","buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662054556?lang=zh_cn&edition=full","pubTime":"2026-08-28 14:47","pubTimestamp":1787899677,"startTime":"0","endTime":"0","summary":"基于充沛的现金流与良好的财务状况,盘龙药业同步推出中期分红与股份回购双重举措,充分彰显管理层对公司长期价值的信心。截至目前,盘龙药业产品已覆盖5600余家等级医疗机构;同步深耕第二、第三终端,精准渗透33000余家零售药房及23000余家基层医疗单元,形成医疗与零售双轮驱动的立体格局。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026082800030469.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002864","BK0239","159399"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662036037","title":"盘龙药业:业务结构升级落地显效,双资质加持打开新增长空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2662036037","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662036037?lang=zh_cn&edition=full","pubTime":"2026-08-28 09:30","pubTimestamp":1787880602,"startTime":"0","endTime":"0","summary":"2026年上半年,盘龙药业保持稳健经营态势,资产规模稳步提升,资产结构持续优化。在内部管控方面,盘龙药业持续提升资金使用效率,严控非必要开支,实现了降本增效的经营目标,上半年销售费用同比下降19.59%。截至半年报披露日,盘龙药业核心产品盘龙七片成功新增纳入国家基本药物目录,形成“医保甲类+基药”双重资质壁垒,进一步夯实细分领域竞争优势。","market":"hk","thumbnail":" http://caiji.3g.cnfol.com/colect/202608/28/20260828353646.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202608/28/20260828353646.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260828/32351157.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["002864","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662033655","title":"股市必读:盘龙药业新发布《关于2026年半年度利润分配方案的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2662033655","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662033655?lang=zh_cn&edition=full","pubTime":"2026-08-28 04:32","pubTimestamp":1787862734,"startTime":"0","endTime":"0","summary":"截至2026年8月27日收盘,盘龙药业报收于22.77元,上涨0.84%,换手率2.92%,成交量2.88万手,成交额6540.25万元。公司公告汇总:截至2026年期末,非经营性资金往来余额合计18,573.89万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800009316.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002864"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662809340","title":"图解盘龙药业中报:第二季度单季净利润同比下降28.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662809340","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662809340?lang=zh_cn&edition=full","pubTime":"2026-08-28 03:28","pubTimestamp":1787858921,"startTime":"0","endTime":"0","summary":"证券之星消息,盘龙药业2026年中报显示,上半年度公司主营收入4.23亿元,同比下降26.38%;归母净利润4237.61万元,同比下降29.53%;扣非净利润3848.82万元,同比下降27.18%;其中2026年第二季度,公司单季度主营收入2.0亿元,同比下降38.22%;单季度归母净利润2061.52万元,同比下降28.63%;单季度扣非净利润1847.4万元,同比下降23.36%;负债率25.97%,投资收益-11.02万元,财务费用-185.95万元,毛利率57.72%。财报数据概要请见下图:本文数据来源于盘龙药业2026年中报,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800006797.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002864"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657565000","title":"股市必读:盘龙药业(002864)8月4日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2657565000","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657565000?lang=zh_cn&edition=full","pubTime":"2026-08-05 03:23","pubTimestamp":1785871429,"startTime":"0","endTime":"0","summary":"截至2026年8月4日收盘,盘龙药业报收于21.24元,上涨1.68%,换手率2.74%,成交量2.7万手,成交额5725.24万元。董秘最新回复投资者: 尊敬的董秘 你好 衷心感谢你们不厌其烦回答投资者的提问。请问贵公司2026年7月31日A股股东人数是多少?根据信息披露相关规定,公司将在定期报告中披露期末股东户数。相关定期数据请留意后续半年报公告,感谢您的理解与支持。当日关注点交易信息汇总:8月4日主力资金净流出12.51万元,占总成交额0.22%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500003878.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002864","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651412594","title":"数十家机构扎堆调研!盘龙药业基药红利释放打开成长空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2651412594","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651412594?lang=zh_cn&edition=full","pubTime":"2026-07-16 16:00","pubTimestamp":1784188801,"startTime":"0","endTime":"0","summary":"在调研活动中,盘龙药业透露了阶段性发展目标。盘龙药业表示,目前公司销售团队全面覆盖三大终端市场,团队战斗力、专业程度可匹配基药落地后的放量节奏。机构普遍认为,人口老龄化持续拉动骨科慢病用药需求增长,骨科中成药赛道长期增量明确,盘龙药业有望持续受益。除此以外,盘龙药业“内生增长+外延发展”双轮驱动战略进一步打开长期想象空间。","market":"sh","thumbnail":" http://caiji.3g.cnfol.com/colect/202607/16/20260716517422.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202607/16/20260716517422.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260716/32309418.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["002864","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651552461","title":"盘龙药业(002864)披露2025年年度权益分派实施公告,7月15日股价上涨2.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651552461","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651552461?lang=zh_cn&edition=full","pubTime":"2026-07-15 22:22","pubTimestamp":1784125333,"startTime":"0","endTime":"0","summary":"截至2026年7月15日收盘,盘龙药业报收于30.65元,较前一交易日上涨2.58%,最新总市值为32.23亿元。该股当日开盘29.31元,最高30.96元,最低29.18元,成交额达2.27亿元,换手率为10.15%。近日,盘龙药业发布《2025年年度权益分派实施公告》。公告显示,公司2025年年度权益分派方案已获2026年5月26日召开的年度股东会审议通过。分红后公司总股本增至136,700,928股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500044918.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002864"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651010437","title":"盘龙药业(002864)披露控股股东持股比例因回购注销被动增加触及1%及5%整数倍公告,7月14日股价上涨2.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651010437","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651010437?lang=zh_cn&edition=full","pubTime":"2026-07-14 22:16","pubTimestamp":1784038582,"startTime":"0","endTime":"0","summary":"截至2026年7月14日收盘,盘龙药业报收于29.88元,较前一交易日上涨2.57%,最新总市值为31.76亿元。该股当日开盘28.74元,最高29.88元,最低28.07元,成交额达2.02亿元,换手率为9.45%。近日,盘龙药业发布《关于控股股东、实际控制人持股比例因公司回购注销被动增加触及1%及5%整数倍的公告》。公告显示,陕西盘龙药业集团股份有限公司于2026年7月13日完成2022年限制性股票回购注销,总股本由106,280,960股减少至105,154,560股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071400049460.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002864","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650590407","title":"盘龙药业:盘龙七片入选2026国家基药目录,凭硬核资质打开业绩增量空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2650590407","media":"中金财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650590407?lang=zh_cn&edition=full","pubTime":"2026-07-10 13:40","pubTimestamp":1783662002,"startTime":"0","endTime":"0","summary":"在此之前,盘龙七片已稳居医保甲类目录、斩获十余项国家级诊疗指南权威推荐,本次入围国家基本药物目录,是产品综合实力的再一次重磅升级。权威资质再次升级要了解盘龙七片此次入选的意义,首先要知道国家基本药物目录是什么。盘龙七片的热销来源于我国广泛的骨科慢病患者基数。这意味着,盘龙七片此次入选国家基本药物目录,将直接为其打开院外市场空间,实现院内院外用药场景的全面打通。","market":"fut","thumbnail":" http://caiji.3g.cnfol.com/colect/202607/10/20260710164482.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202607/10/20260710164482.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260710/32304048.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","002864"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645888742","title":"创新药概念震荡拉升,盘龙药业一度涨超9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645888742","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645888742?lang=zh_cn&edition=full","pubTime":"2026-06-23 14:14","pubTimestamp":1782195288,"startTime":"0","endTime":"0","summary":"6月23日,创新药概念震荡拉升,盘龙药业一度大涨超9%。公司层面,盘龙药业是集药材规范化种植、药品生产、研发、销售为一体的现代化高新技术企业,以医药制造为核心主营业务,产业链涵盖现代中药、医药商业和大健康。长城证券指出,盘龙药业作为风湿骨科类中药龙头企业,将持续受益政策红利、人口老龄化趋势加速和消费升级趋势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026062300019848.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","002864","159992","BK1161","BK1574","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640139113","title":"盘龙药业:截至2026年一季度公司已完成509个中药配方颗粒品种备案","url":"https://stock-news.laohu8.com/highlight/detail?id=2640139113","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640139113?lang=zh_cn&edition=full","pubTime":"2026-06-04 11:34","pubTimestamp":1780544064,"startTime":"0","endTime":"0","summary":"证券之星消息,盘龙药业06月03日在投资者关系平台上答复投资者关心的问题。截至2026年一季度公司已完成509个中药配方颗粒品种备案,智能化产线已全面建成投产,具备全品种量产能力,同步组建了专项业务中心,依托现有覆盖全国的成熟营销网络,公司正积极推进全国各省份的挂网准入工作。后续公司也将持续根据行业政策、市场变化动态优化经营策略,稳步推进中药配方颗粒业务落地。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060400014399.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002864"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640495861","title":"盘龙药业(002864)披露向2026年股票期权激励计划激励对象授予股票期权的公告,6月1日股价上涨1.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640495861","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640495861?lang=zh_cn&edition=full","pubTime":"2026-06-01 18:03","pubTimestamp":1780308189,"startTime":"0","endTime":"0","summary":"截至2026年6月1日收盘,盘龙药业报收于29.33元,较前一交易日上涨1.91%,最新总市值为31.17亿元。公司于近日披露《关于向2026年股票期权激励计划激励对象授予股票期权的公告》。公告显示,陕西盘龙药业集团股份有限公司于2026年5月29日召开董事会,确定当日为股票期权授予日,向60名激励对象授予37.35万份股票期权,行权价格为31.11元/份。本次授予符合公司股权激励计划规定条件,不会导致股权分布不符合上市条件。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100028562.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002864","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638850542","title":"盘龙药业(002864)披露2026年股票期权激励计划内幕信息知情人及激励对象买卖公司股票情况自查报告,5月27日股价下跌0.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638850542","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2638850542?lang=zh_cn&edition=full","pubTime":"2026-05-27 17:36","pubTimestamp":1779874617,"startTime":"0","endTime":"0","summary":"截至2026年5月27日收盘,盘龙药业报收于28.45元,较前一交易日下跌0.39%,最新总市值为30.24亿元。该股当日开盘28.55元,最高28.72元,最低28.0元,成交额达4864.33万元,换手率为2.33%。盘龙药业于近日披露《关于公司2026年股票期权激励计划内幕信息知情人及激励对象买卖公司股票情况的自查报告》。公司未发现内幕信息泄露或利用内幕信息进行交易的情形。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052700034733.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002864","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635430783","title":"盘龙药业(002864)披露2026年股票期权激励计划(草案),5月13日股价上涨2.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635430783","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2635430783?lang=zh_cn&edition=full","pubTime":"2026-05-13 18:29","pubTimestamp":1778668186,"startTime":"0","endTime":"0","summary":"截至2026年5月13日收盘,盘龙药业报收于31.61元,较前一交易日上涨2.96%,最新总市值为33.6亿元。该股当日开盘31.31元,最高32.05元,最低31.27元,成交额达1.3亿元,换手率为5.58%。近日,盘龙药业披露《2026年股票期权激励计划(草案)》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051300034608.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002864"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633275186","title":"盘龙药业(002864)披露召开2025年年度股东会的通知,5月6日股价上涨0.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633275186","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2633275186?lang=zh_cn&edition=full","pubTime":"2026-05-06 18:12","pubTimestamp":1778062323,"startTime":"0","endTime":"0","summary":"截至2026年5月6日收盘,盘龙药业报收于30.3元,较前一交易日上涨0.2%,最新总市值为32.2亿元。该股当日开盘30.38元,最高30.43元,最低30.1元,成交额达5557.01万元,换手率为2.49%。公司于近日披露《关于召开2025年年度股东会的通知》。公告显示,陕西盘龙药业集团股份有限公司将于2026年5月26日召开2025年年度股东会,会议由董事会召集,现场会议地点为西安市灞桥区现代纺织产业园灞柳二路2801号公司二楼会议室。股权登记日为2026年5月19日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050600029414.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002864","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1789526026795,"stockEarnings":[{"period":"1week","weight":-0.0804},{"period":"1month","weight":-0.0911},{"period":"3month","weight":-0.004},{"period":"6month","weight":-0.2085},{"period":"1year","weight":-0.1143},{"period":"ytd","weight":-0.1341}],"compareEarnings":[{"period":"1week","weight":-0.0194},{"period":"1month","weight":-0.016},{"period":"3month","weight":-0.0593},{"period":"6month","weight":-0.0355},{"period":"1year","weight":0.001},{"period":"ytd","weight":-0.0263}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"陕西盘龙药业集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"19294人(较上一季度减少12.33%)","perCapita":"5110股","listingDate":"2017-11-16","address":"陕西省商洛市柞水县盘龙生态产业园","registeredCapital":"13670万元","survey":" 陕西盘龙药业集团股份有限公司的主营业务是药材规范化种植、药品生产、研发、销售。公司的主要产品是盘龙七片、盘龙七药酒、金茵利胆胶囊、克比热提片、复方醋酸棉酚片、醋酸棉酚原料药、骨胶归珍片、盘龙七贴。截至本报告期末,公司荣获“国家级绿色工厂”及第七届“全国文明单位”,成功取得中国合格评定国家认可委员会(CNAS)实验室认可证书;2026年上半年新增获评“国家知识产权强国建设示范创建对象”“省级高技能人才培训基地”,入选“全国‘双化协同’典型案例”等多项荣誉资质。","listedPrice":10.03},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"盘龙药业(002864)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供盘龙药业(002864)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"盘龙药业,002864,盘龙药业股票,盘龙药业股票老虎,盘龙药业股票老虎国际,盘龙药业行情,盘龙药业股票行情,盘龙药业股价,盘龙药业股市,盘龙药业股票价格,盘龙药业股票交易,盘龙药业股票购买,盘龙药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"盘龙药业(002864)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供盘龙药业(002864)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}